BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30953504)

  • 1. Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient.
    Baquedano Lobera I; Izquierdo Álvarez S; Oliván Del Cacho MJ
    BMC Pediatr; 2019 Apr; 19(1):92. PubMed ID: 30953504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
    Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
    Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
    Ueda K; Yaoita M; Niihori T; Aoki Y; Okamoto N
    Am J Med Genet A; 2017 Sep; 173(9):2346-2352. PubMed ID: 28650561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of craniofacial and dental findings of the RASopathies.
    Cao H; Alrejaye N; Klein OD; Goodwin AF; Oberoi S
    Orthod Craniofac Res; 2017 Jun; 20 Suppl 1(Suppl 1):32-38. PubMed ID: 28643916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arnold-Chiari malformation in Noonan syndrome and other syndromes of the RAS/MAPK pathway].
    Ejarque I; Millán-Salvador JM; Oltra S; Pesudo-Martínez JV; Beneyto M; Pérez-Aytés A
    Rev Neurol; 2015 May; 60(9):408-12. PubMed ID: 25912702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
    Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
    Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome.
    Ekvall S; Sjörs K; Jonzon A; Vihinen M; Annerén G; Bondeson ML
    Am J Med Genet A; 2014 Mar; 164A(3):579-87. PubMed ID: 24357598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular analysis of RASopathies in a group of Turkish patients.
    Şimşek-Kiper PÖ; Alanay Y; Gülhan B; Lissewski C; Türkyilmaz D; Alehan D; Cetin M; Utine GE; Zenker M; Boduroğlu K
    Clin Genet; 2013 Feb; 83(2):181-6. PubMed ID: 22420426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
    Thiel C; Wilken M; Zenker M; Sticht H; Fahsold R; Gusek-Schneider GC; Rauch A
    Am J Med Genet A; 2009 Jun; 149A(6):1263-7. PubMed ID: 19449407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New insight of craniofacial and oral findings of the RASopathies].
    Cao HT; Yang YJ; Zheng Q; Shi B; Li CH
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Dec; 53(12):858-861. PubMed ID: 30522213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of Growth Failure in Rasopathies.
    Aftab S; Dattani MT
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):447-458. PubMed ID: 31115196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A severe form of Noonan syndrome and autosomal dominant café-au-lait spots - evidence for different genetic origins.
    Nyström AM; Ekvall S; Strömberg B; Holmström G; Thuresson AC; Annerén G; Bondeson ML
    Acta Paediatr; 2009 Apr; 98(4):693-8. PubMed ID: 19120036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASopathies: Dermatologists' viewpoints.
    Palit A; Inamadar AC
    Indian J Dermatol Venereol Leprol; 2022; 88(4):452-463. PubMed ID: 35138057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in RASopathies.
    Aoki Y; Niihori T; Inoue S; Matsubara Y
    J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatological manifestations, management, and care in RASopathies.
    Kavamura MI; Leoni C; Neri G
    Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):452-458. PubMed ID: 36541891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
    Bezniakow N; Gos M; Obersztyn E
    Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple café au lait spots in familial patients with MAP2K2 mutation.
    Takenouchi T; Shimizu A; Torii C; Kosaki R; Takahashi T; Saya H; Kosaki K
    Am J Med Genet A; 2014 Feb; 164A(2):392-6. PubMed ID: 24311457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costello syndrome and related disorders.
    Quezada E; Gripp KW
    Curr Opin Pediatr; 2007 Dec; 19(6):636-44. PubMed ID: 18025929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.
    Fowlkes JL; Thrailkill KM; Bunn RC
    Bone; 2021 Nov; 152():116060. PubMed ID: 34144233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.